Research Article
Nimotuzumab Concurrent with Gemcitabine as First-Line Treatment of Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Table 3
List of treatment-related adverse events according to CTCAE
(version 4.0).
| | Treatment-related adverse event (TRAE) | No. of patients with the TRAE | Adverse events severity | | Grade 1-2 | |
| | Anorexia | 1 | 1 | — | | Alkaline phosphatase increased | 3 | 3 | — | | Alanine aminotransferase increased | 1 | 1 | — | | Aspartate aminotransferase increased | 1 | 1 | — | | Anemia | 1 | 1 | — | | Glottis edema | 1 | — | 1 | | Headache | 4 | 3 | 1 | | Hematuria | 1 | 1 | — | | Legs muscle weakness | 1 | | 1 | | Leukopenia | 1 | 1 | | | Myalgia | 4 | 4 | — | | Nauseas | 5 | 5 | — | | Perioral cyanosis | 1 | 1 | | | Rash | 1 | — | 1 |
|
|
CTCAE: Common Terminology Criteria for Adverse Events. |
